Screener
Denali Therapeutics Inc. DNLI Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Therapeutics Segment / Three Months Ended June 30, 2026 | Therapeutics Segment / Three Months Ended June 30, 2025 | Therapeutics Segment / Six Months Ended June 30, 2026 | Therapeutics Segment / Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Personnel related selling, general and administrative expenses | 22,921 | 20,115 | 45,485 | 38,853 |
| Other selling, general and administrative expenses | 13,362 | 12,152 | 24,309 | 22,767 |
| Total selling, general and administrative expenses | 36,283 | 32,267 | 69,794 | 61,620 |
| Intangible asset amortization | $750 | — | $750 | — |
| Segment operating expenses | 134,145 | 134,963 | 271,502 | 280,543 |
| Segment loss from operations | (130,541) | (134,963) | (267,898) | (280,543) |
| Segment interest and other income, net | 2,988 | 10,844 | 11,898 | 23,454 |
| Segment net loss | $(127,553) | $(124,119) | $(256,000) | $(257,089) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s business segments — operating income (loss)?
- Denali Therapeutics Inc. (DNLI) reported business segments — operating income (loss) of -$130.54M in Q2 2026.
- How has Denali Therapeutics Inc.'s business segments — operating income (loss) changed year-over-year?
- Denali Therapeutics Inc.'s business segments — operating income (loss) increased by 3.3% year-over-year, from -$134.96M to -$130.54M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — operating income (loss)?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — operating income (loss) has grown at a 17.7% compound annual growth rate (CAGR), from -$340.74M to -$555.34M.
- What does business segments — operating income (loss) mean?
- Calculated as total segment revenue minus total operating expenses, representing the profitability of the core business operations. For early-stage biotechnology companies, this is typically a loss, reflecting heavy investment in pipeline development. It serves as a primary indicator of the company's progress toward commercial viability.
Ask your AI about Denali Therapeutics Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude